--- title: "Rafael Holdings (RFL) stock: news and investor profile" url: "https://aibio.space/companies/rafael/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Rafael Holdings, Inc. (NYSE: RFL), United States. Listing facts, related biotech companies and news on aibio.space." --- RFL Rafael Holdings, Inc. NYSE · United States # Rafael Holdings (RFL) news Rafael Holdings, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker RFL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest Rafael Holdings news We have not published a story on Rafael Holdings yet. When there is news, it will appear here. ## Rafael Holdings at a glance - **Ticker**: RFL - **Listing**: NYSE - **Country**: United States - **Cash, Jul 31, 2026**: $22.1 million ### Related companies - [Beroni Group](https://aibio.space/companies/beroni/) OTC: BNIGF - [CARLSMED, INC.](https://aibio.space/companies/carlsmed/) NASDAQ: CARL - [Embecta](https://aibio.space/companies/embecta/) NASDAQ: EMBC - [RadNet](https://aibio.space/companies/radnet/) NASDAQ: RDNT - [ProPhase Labs](https://aibio.space/companies/prophase-labs/) OTC: PRPH - [MERIT MEDICAL SYSTEMS INC](https://aibio.space/companies/merit-medical-systems/) NASDAQ: MMSI - [Warby Parker](https://aibio.space/companies/warby-parker/) NYSE: WRBY - [Renalytix](https://aibio.space/companies/renalytix/) OTC: RNLXY ### Also on NYSE - [UL Solutions](https://aibio.space/companies/ul-solutions/) ULS - [WEST PHARMACEUTICAL SERVICES INC](https://aibio.space/companies/west-pharmaceutical-services/) WST - [Evommune](https://aibio.space/companies/evommune/) EVMN - [LABCORP HOLDINGS INC.](https://aibio.space/companies/labcorp/) LH - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) RCUS - [RESMED INC](https://aibio.space/companies/resmed/) RMD ## What Rafael Holdings does Rafael Holdings is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies developing pharmaceuticals and medical devices. Its lead candidate, Trappsol Cyclo (remibetadex), is an investigational therapy for Niemann-Pick Disease Type C, a rare, fatal and progressive genetic disorder. The company says it has completed the pivotal Phase 3 trial and submitted a New Drug Application to the FDA on October 28, 2026. The Phase 3 study did not meet its primary endpoint in the overall population, while a prespecified analysis in patients receiving background miglustat and/or leucine therapy showed a statistically significant treatment benefit. Its subsidiary Cyclo became wholly owned through a merger completed March 25, 2025. Other holdings include LipoMedix, a clinical-stage company developing Promitil, a liposome-based cancer candidate; Barer Institute, which holds early-stage cancer assets; Cornerstone Pharmaceuticals, a cancer metabolism-based therapeutics company; Rafael Medical Devices, an orthopedic-focused device company; and Day Three Labs, which provides technology to third-party manufacturers. | Product or program | What it is | Stage | |---|---|---| | Trappsol Cyclo (remibetadex) | Investigational therapy for Niemann-Pick Disease Type C | pivotal Phase 3 completed; NDA submitted October 28, 2026 | | Promitil | Liposome-delivery candidate for cancer, developed by LipoMedix | clinical stage | Summarised from the company's [10-K filed Oct 29, 2026](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm). ## Rafael Holdings annual financials | Line | FY ended Jul 31, 2026 | FY ended Jul 31, 2025 | |---|---|---| | Revenue | | [$917,000](https://www.sec.gov/Archives/edgar/data/1713863/000121390025103549/) | | Research and development | [$24.3 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | [$12.8 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | | Net income (loss) | [-$29.6 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | [-$30.5 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | | Cash from operations | [-$30.0 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | [-$18.9 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | | Cash and equivalents | [$22.1 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/) | [$52.8 million](https://www.sec.gov/Archives/edgar/data/1713863/000121390026067560/) | Latest balance sheet, Jul 31, 2026 (10-K): cash and equivalents $22.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Rafael Holdings What is the ticker symbol of Rafael Holdings? Rafael Holdings, Inc. trades under the ticker RFL on NYSE. Where is Rafael Holdings listed? Rafael Holdings, Inc. is listed on NYSE. Which country or territory is Rafael Holdings listed under? Our directory records Rafael Holdings, Inc. under United States. Does aibio.space cover Rafael Holdings? aibio.space lists Rafael Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What does Rafael Holdings develop? Rafael Holdings is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies developing pharmaceuticals and medical devices. Its lead candidate, Trappsol Cyclo (remibetadex), is an investigational therapy for Niemann-Pick Disease Type C, a rare, fatal and progressive genetic disorder. What is Trappsol Cyclo (remibetadex) from Rafael Holdings? Trappsol Cyclo (remibetadex): Investigational therapy for Niemann-Pick Disease Type C Stage: pivotal Phase 3 completed; NDA submitted October 28, 2026. What is Promitil from Rafael Holdings? Promitil: Liposome-delivery candidate for cancer, developed by LipoMedix Stage: clinical stage. Is Rafael Holdings profitable? Rafael Holdings, Inc. reported a net loss of $29.6 million for the fiscal year ended Jul 31, 2026, and used $30.0 million of cash in operations, per its annual report to the SEC. How much does Rafael Holdings spend on research and development? $24.3 million in the fiscal year ended Jul 31, 2026, per its annual report. How much cash does Rafael Holdings have? $22.1 million in cash at Jul 31, 2026, per its 10-K. ## Investor discussion: Rafael Holdings Members talk about Rafael Holdings (RFL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Rafael Holdings, newest first. Each line links the filing it comes from. 1. 2026-10-29 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1713863/000121390026113659/ea0309115-10k_rafael.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NYSE:RFL on TradingView](https://www.tradingview.com/symbols/NYSE-RFL/). ## Listing details Rafael Holdings, Inc. is a public biotech or pharmaceutical company listed on NYSE under the ticker RFL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Rafael Holdings, Inc. - **Ticker**: RFL - **Listing**: NYSE - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/rafael/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rafael Holdings (RFL) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/rafael/